Certolizumab pegol: new opportunities for treatment of moderate to severe plaque psoriasis
Authors:
Open Access
- 17 December 2019
- journal article
- Published by Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov in Vestnik dermatologii i venerologii
- Vol. 95 (5) , 50-57
Abstract
Tumor necrosis factor alpha (TNF-α) is one of the key inflammatory cytokines in the pathogenesis of psoriasis and psoriatic arthritis, and its inhibition with genetically engineered biological drugs ensures control of the main symptoms of these diseases. Certolizumab pegol is a PEGylated (linked to polyethylene glycol) Fab’ fragment of a monoclonal antibody that inhibits human TNF-α. It is approved for treatment of moderate to severe plaque psoriasis and psoriatic arthritis. This review summarizes the results of randomized clinical trials of efficacy and safety of certolizumab pegol in plaque psoriasis (CIMPASI 1, CIMPASI 2, and CIMPACT) and psoriatic arthritis (Rapid-PsA). The represented data demonstrate high efficacy of certolizumab pegol is bio-naïve patients and in patients previously exposed to other TNF inhibitors or IL17 inhibitors. The absence of the Fc-fragment in certolizumab pegol ensures minimal to no placental transfer of the drug and enables its usage during the entire pregnancy.Conflict of interest: the authors state that there is no potential conflict of interest requiring disclosure in this article.Keywords
This publication has 28 references indexed in Scilit:
- Psoriasis Pathogenesis and TreatmentInternational Journal of Molecular Sciences, 2019
- Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transitionNature Reviews Rheumatology, 2019
- Cross‐sectional multicenter observational study of psoriatic arthritis in Japanese patients: Relationship between skin and joint symptoms and results of treatment with tumor necrosis factor‐α inhibitorsThe Journal of Dermatology, 2019
- Psoriatic ArthritisNew England Journal of Medicine, 2017
- PsoriasisNature Reviews Disease Primers, 2016
- Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with PsoriasisDrugs, 2014
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive reviewPharmacology & Therapeutics, 2008
- Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor α agentsInflammatory Bowel Diseases, 2007
- Psoriatic arthritis as a distinct disease entityJournal of Postgraduate Medicine, 2007
- Psoriatic arthritis: epidemiology, clinical features, course, and outcomeAnnals of the Rheumatic Diseases, 2005